Lexicon Pharmaceuticals Inc (LXRX)

Dec 20, 2024

Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista? (sotagliflozin) - Marketscreener.com

Dec 20, 2024

Dec 20, 2024

Stocks to Watch: Rumble, Lexicon Pharmaceuticals - MarketWatch

Dec 20, 2024

Dec 20, 2024

FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha

Dec 20, 2024

Dec 20, 2024

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times

Dec 20, 2024

Dec 20, 2024

Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan

Dec 20, 2024

Dec 18, 2024

Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com

Dec 18, 2024

Dec 10, 2024

Point72 Asset Management L.P. Sells 2,891,141 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat

Dec 10, 2024

Dec 06, 2024

Fmr LLC Has $78.29 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat

Dec 06, 2024

Dec 05, 2024

Lexicon Pharmaceuticals (LXRX) Stock Dips Amid Market Volatility - GuruFocus.com

Dec 05, 2024

Dec 04, 2024

Lexicon Pharmaceuticals stock hits 52-week low at $0.73 By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 03, 2024

Lexicon Pharmaceuticals stock hits 52-week low at $0.73 - Investing.com India

Dec 03, 2024

Nov 30, 2024

Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat

Nov 30, 2024

Nov 28, 2024

Lexicon completes subject enrolment for DPNP trial of LX9211 - Clinical Trials Arena

Nov 28, 2024

Nov 27, 2024

2 Generic Drug Stocks Ready to Surge in 2025 - Benzinga

Nov 27, 2024

Nov 27, 2024

The Escalator: Lexicon Pharmaceuticals, Reckitt, NIH and more - MM+M Online

Nov 27, 2024

Nov 26, 2024

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times

Nov 26, 2024

Nov 26, 2024

Lexicon Pharma Hits 120% Enrollment Target in Key Pain Drug Trial, Ahead of Schedule | LXRX Stock News - StockTitan

Nov 26, 2024

Nov 26, 2024

Lexicon Pharmaceuticals to Participate in December Investor Conferences - The Manila Times

Nov 26, 2024

Nov 25, 2024

Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December | LXRX Stock News - StockTitan

Nov 25, 2024

Nov 25, 2024

Lexicon Pharmaceuticals shares target cut, retains buy rating on FDA letter - Investing.com UK

Nov 25, 2024

Nov 25, 2024

Lexicon pivots back to pipeline after FDA rejection - The Pharma Letter

Nov 25, 2024

Nov 23, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC - MarketBeat

Nov 23, 2024

Nov 22, 2024

Lexicon Pharmaceuticals to cut 60% of workforce By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 22, 2024

Lexicon Pharmaceuticals to cut 60% of workforce - Investing.com India

Nov 22, 2024

Nov 22, 2024

Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown - Citeline News & Insights

Nov 22, 2024

Nov 22, 2024

Diabetes Endpoints: A1C Reduction Is ‘Still Enough,’ Just Not For Lexicon’s Sotagliflozin, US FDA Says - Citeline

Nov 22, 2024

Nov 22, 2024

Lexicon to disband sales team, lay off 60% of staff - BioPharma Dive

Nov 22, 2024

Nov 22, 2024

Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback - Reuters.com

Nov 22, 2024

Nov 22, 2024

Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization - MarketWatch

Nov 22, 2024

Nov 22, 2024

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - The Manila Times

Nov 22, 2024

Nov 22, 2024

Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - StreetInsider.com

Nov 22, 2024

Nov 22, 2024

Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista | LXRX Stock News - StockTitan

Nov 22, 2024

Nov 21, 2024

Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com Canada

Nov 21, 2024

Nov 21, 2024

Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com

Nov 21, 2024

Nov 21, 2024

Lexicon Appoints Ivan H. Cheung to Board of Directors - The Manila Times

Nov 21, 2024

Nov 21, 2024

Lexicon Appoints Ivan Cheung to Board of Directors - citybiz

Nov 21, 2024

Nov 20, 2024

Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India

Nov 20, 2024

Nov 20, 2024

Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com

Nov 20, 2024

Nov 20, 2024

Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com

Nov 20, 2024

Nov 18, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance

Nov 18, 2024

Nov 18, 2024

Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat

Nov 18, 2024

Nov 15, 2024

Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India

Nov 15, 2024

Nov 15, 2024

What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat

Nov 15, 2024

Nov 14, 2024

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times

Nov 14, 2024

Nov 14, 2024

Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024